Tag Archives: CNS disease

BIO Investor Forum Company Snapshot: Vaccinex

Vaccinex

Recently, the CEO of Prosensa provided their company’s perspective participating in last year’s BIO Investor Forum. Looking ahead at this year’s event, we spoke to the President & CEO of Vaccinex, Dr. Maurice Zauderer. They will be presenting in the regular private track, which features later-stage private companies. Read below to learn more about this biotech.   Company Snapshot What is your company’s lead product or technology? Vaccinex’s lead product, VX15, is an antibody to semaphorin Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

#BIO2013 Company Snapshot: Trigemina

Trigemina

The BIO One-on-One Partnering System has been working overtime with 15 percent more requests than the previous year! With the BIO International Convention now officially a week away, we’re featuring another presenting company in our Snapshot Series. We spoke to Trigemina, and you can find their responses below. And catch their presentation Monday, 4/22 at 2:00 p.m. in the Chicago Cubs Room, located right outside the main entrance of the BIO Business Forum.   Company Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO CEO Company Snapshot: NuPathe Inc.

NuPathe

The Company Snapshots have returned for our next One-on-One Partnering event, the BIO CEO & Investor Conference, taking place in New York City this February.  The companies that will be profiled in these snapshots will all be presenting at the event, and we hope this provides the opportunity to learn more about them, and catch up on what’s new. For our first Snapshot for the BIO CEO event, we’ve spoken with NuPathe Inc. about their Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

PTC Therapeutics Announces Collaboration with Roche

PTC Therapeutics, Inc. announced a research collaboration and licensing agreement with Roche for development of orally bioavailable small molecules using PTC’s technology, Gene Expression Modulation by Small-molecules (GEMS™). As part of the collaboration, Roche is paying PTC Therapeutics $12 million as part of an agreement to develop small molecule CNS disease drugs. Subject to meeting milestones, there is the potential for PTC to earn up to $239 million in research, development, regulatory and commercial milestone Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,